MYC基因重排DLBCL患者的PET应答异常模式
该研究基于两项HOVON试验,比较81例MYC阳性与129例MYC阴性DLBCL患者的中期和终末PET/CT应答模式。MYC阳性患者终末PET阳性率显著更高(32.5% vs 15.7%,p=0.004),且中期阴性转终末阳性的比例显著更高(23.2% vs 2%,p=0.002),并出现初始未受累部位的新发病灶。
要点
- MYC阳性DLBCL终末PET阳性率32.5%,显著高于MYC阴性15.7%(p=0.004)。
- MYC阳性患者中期PET阴性转终末阳性比例23.2%,显著高于MYC阴性2%(p=0.002)。
- MYC阳性患者终末PET阳性时80.8%同时出现病灶SUV与MTV较中期升高。
核心结论
- MYC阳性DLBCL患者较MYC阴性患者呈现异常PET应答模式,表现为中期阴性后治疗中进展更频繁及初始未受累部位出现新病灶。
研究设计与样本
- 回顾性分析2项HOVON试验中81例MYC阳性与129例MYC阴性DLBCL患者的中期和终末PET/CT,采用Deauville 5分法评估。
主要发现
- MYC阳性患者终末PET阳性率32.5%,显著高于MYC阴性15.7%(p=0.004);中期PET阳性率两组相当(28.8% vs 23.8%)。
- MYC阳性患者中期PET阴性转终末阳性比例23.2%,显著高于MYC阴性2%(p=0.002)。
- 9例(34.6%)MYC阳性患者终末PET显示初始未受累部位新发病灶,MYC阴性仅1例(5.3%)。
- 终末PET阳性MYC阳性患者中80.8%同时出现病灶SUV与MTV较中期升高;MYC阴性患者中31.6% SUV升高、42.1% MTV升高。
- 中期与终末PET的阴性预测值在两组均较高(81.8%–94.1%);终末PET阳性预测值在MYC阳性患者最高(61.5%)。
关键数值与推荐
- Deauville 5分法:DS1-3为阴性,DS4-5为阳性。
- 预测值计算采用2年总生存。
临床怎么用
- 对MYC阳性DLBCL患者,中期PET阴性后仍需警惕治疗中进展,终末PET评估需关注初始未受累部位的新发病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: MYC gene rearrangements in diffuse large B-cell lymphoma (DLBCL) patients are associated with poor prognosis. Our aim was to compare patterns of 2[18F]fluoro-2-deoxy-D-glucose positron emission tomography computed tomography (PET/CT) response in MYC + and MYC- DLBCL patients. METHODS: Interim PET/CT (I-PET) and end of treatment PET/CT (EoT-PET) scans of 81 MYC + and 129 MYC- DLBCL patients from 2 HOVON trials were reviewed using the Deauville 5-point scale (DS). DS1-3 was regarded as negative and DS4-5 as positive. Standardized uptake values (SUV) and metabolic tumor volume (MTV) were quantified at baseline, I-PET, and EoT-PET. Negative (NPV) and positive predictive values (PPV) were calculated using 2-year overall survival. RESULTS: MYC + DLBCL patients had significantly more positive EoT-PET scans than MYC- patients (32.5 vs 15.7%, p = 0.004). I-PET positivity rates were comparable (28.8 vs 23.8%). In MYC + patients 23.2% of the I-PET negative patients converted to positive at EoT-PET, vs only 2% for the MYC- patients (p = 0.002). Nine (34.6%) MYC + DLBCL showed initially uninvolved localizations at EoT-PET, compared to one (5.3%) MYC- patient. A total of 80.8% of EoT-PET positive MYC + patients showed both increased lesional SUV and MTV compared to I-PET. In MYC- patients, 31.6% showed increased SUV and 42.1% showed increased MTV. NPV of I-PET and EoT-PET was high for both MYC subgroups (81.8-94.1%). PPV was highest at EoT-PET for MYC + patients (61.5%). CONCLUSION: MYC + DLBCL patients demonstrate aberrant PET response patterns compared to MYC- patients with more frequent progression during treatment after I-PET negative assessment and new lesions at sites that were not initially involved. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: HOVON-84: EudraCT: 2006-005,174-42, retrospectively registered 01-08-2008. HOVON-130: EudraCT: 2014-002,654-39, registered 26-01-2015.
引用
- Eertink JJ, Arens AIJ, Huijbregts JE, et al. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. Eur J Nucl Med Mol Imaging. 2021. PMID: 34476551. doi:10.1007/s00259-021-05498-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。